However, studies on SGLT2 inhibitors in cirrhotic patients with ascites are limited.<h4>Objectives</h4>The objective of this study is to evaluate changes in urine parameters in cirrhotic patients with ascites treated with dapagliflozin.<h4>Methods</h4>This randomized, double-blind, placebo-controlled, crossover trial enrolled 10 patients with Child-Pugh Class B or C cirrhosis who had persistently moderate or tense ascites. Here, SLC5A2 is linked to Cirrhosis.